HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
Share
Why It Matters
An expert analyst still thinks SpyGlass Pharma is a good investment. This suggests the company's story and plans have not changed much.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.